The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 04, 2025

Filed:

Dec. 21, 2018
Applicant:

Genzyme Corporation, Cambridge, MA (US);

Inventors:

Alexandra Joseph, Lexington, MA (US);

Johnson Tran, Sacramento, CA (US);

Susan M. Richards, Sudbury, MA (US);

Assignee:

Genzyme Corporation, Cambridge, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/519 (2006.01); A61K 9/00 (2006.01); A61K 31/365 (2006.01); A61K 31/52 (2006.01); A61K 31/675 (2006.01); A61K 31/69 (2006.01); A61K 38/13 (2006.01); A61K 38/47 (2006.01); A61K 39/395 (2006.01); A61P 3/00 (2006.01); C12Q 1/6883 (2018.01); G01N 33/68 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/519 (2013.01); A61K 9/0019 (2013.01); A61K 31/365 (2013.01); A61K 31/52 (2013.01); A61K 31/675 (2013.01); A61K 31/69 (2013.01); A61K 38/13 (2013.01); A61K 38/47 (2013.01); A61K 39/395 (2013.01); A61K 39/3955 (2013.01); A61P 3/00 (2018.01); C12Q 1/6883 (2013.01); C12Y 302/0102 (2013.01); C12Y 302/01022 (2013.01); G01N 33/6893 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); C12Q 2600/158 (2013.01); G01N 2800/38 (2013.01); G01N 2800/52 (2013.01);
Abstract

The present application provides methods of treating a disease, such as Pompe disease, in a subject, comprising detecting an erythropoiesis biomarker in a sample of the subject after administration of methotrexate and a therapeutic agent to the subject, and administering further treatment with or without concurrently administering additional immune tolerance induction or immunosuppression therapy based on the level of the erythropoiesis biomarker. Further provided by the present application are methods and kits for assessing the level of immune tolerance to a therapeutic agent in a subject based on detection of an erythropoiesis biomarker after administration of methotrexate and the therapeutic agent to the subject.


Find Patent Forward Citations

Loading…